
Experimental
Control
Risk Ratio
Risk Ratio
Study or Subgroup
Events Total Events Total Weight M-H, Random, 95% CI
M-H, Random, 95% CI
29060/ 449 (A) 19 108 4 55 0.7% 2.42 [0.87, 6.76]
29060/ 449 (B) 33 112 4 55 0.7% 4.05 [1.51, 10.86]
29060/448 (A) 27 106 6 51 1.0% 2.17 [0.95, 4.91]
29060/448 (B) 30 106 6 52 1.0% 2.45 [1.09, 5.52]
29060/785 (A) 14 103 2 27 0.4% 1.83 [0.44, 7.59]
29060/785 (B) 16 96 2 26 0.4% 2.17 [0.53, 8.83]
29060/785 (C) 19 107 2 26 0.4% 2.31 [0.57, 9.29]
29060/785 (D) 16 100 2 26 0.4% 2.08 [0.51, 8.48]
Andreoli et al. 2002 33 127 13 128 1.6% 2.56 [1.41, 4.63]
Ball et al (2014) 19 79 7 79 1.0% 2.71 [1.21, 6.09]
Bose 2008 19 130 8 134 1.1% 2.45 [1.11, 5.39]
Burke et al. (A) 2002 21 119 6 122 0.9% 3.59 [1.50, 8.58]
Burke et al. (B) 2002 14 125 6 122 0.8% 2.28 [0.90, 5.73]
Burke et al. (C) 2002 22 125 6 122 0.9% 3.58 [1.50, 8.52]
Cassano et al. 1986 29 161 6 149 1.0% 4.47 [1.91, 10.47]
Claghorn 1992a 13 36 2 35 0.4% 6.32 [1.54, 25.99]
Claghorn et al. 1996 11 47 4 46 0.7% 2.69 [0.92, 7.84]
Cohn et al. 1985 15 54 3 58 0.5% 5.37 [1.65, 17.53]
Cohn et al. 1991 13 40 7 40 1.0% 1.86 [0.83, 4.16]
Coleman et al. 1999 26 115 14 121 1.6% 1.95 [1.08, 3.55]
Coleman et al. 2001 18 154 24 152 1.7% 0.74 [0.42, 1.31]
Corrigan et al. 2000 6 33 7 34 0.8% 0.88 [0.33, 2.35]
Croft et al. 1999 37 118 12 119 1.6% 3.11 [1.71, 5.66]
Davidson et al. 2002 41 111 24 116 2.3% 1.79 [1.16, 2.75]
Dominguez et al. 1985 14 35 1 31 0.2% 12.40 [1.73, 88.95]
Dubé et al. 2009 7 62 5 138 0.6% 3.12 [1.03, 9.43]
Dunbar et al. 1991 67 240 29 240 2.5% 2.31 [1.55, 3.44]
Dunlop et al (A) 15 105 3 20 0.6% 0.95 [0.30, 2.99]
Dunlop et al (B) 33 104 3 19 0.6% 2.01 [0.69, 5.89]
Dunlop et al (C) 32 107 3 19 0.6% 1.89 [0.64, 5.57]
Fabre 1992 13 39 2 38 0.4% 6.33 [1.53, 26.20]
Fabre et al. 1987 17 72 0 12 0.1% 6.23 [0.40, 97.35]
Fabre et al. 1995 94 278 14 91 1.9% 2.20 [1.32, 3.66]
Fabre et al. 1996 14 46 8 44 1.1% 1.67 [0.78, 3.59]
Fava et al. 2005 4 47 7 43 0.6% 0.52 [0.16, 1.66]
Feighner et al. 1989a 16 51 8 48 1.1% 1.88 [0.89, 3.99]
Feighner et al. 1989b 11 31 3 19 0.6% 2.25 [0.72, 7.04]
Feighner et al. 1999 120 521 14 129 1.9% 2.12 [1.26, 3.57]
Goldstein et al (2002) 6 33 9 70 0.8% 1.41 [0.55, 3.64]
Goldstein et al, 2004 14 87 2 89 0.4% 7.16 [1.68, 30.58]
Griebel et al. 2012 a 8 84 4 75 0.6% 1.79 [0.56, 5.69]
Griebel et al. 2012 b 19 80 5 77 0.8% 3.66 [1.44, 9.31]
Higuchi et al. (A) 2011 27 161 7 86 1.1% 2.06 [0.94, 4.54]
Higuchi et al. (B) 2011 14 83 7 86 0.9% 2.07 [0.88, 4.88]
Kasper (A) 2005 12 173 2 90 0.4% 3.12 [0.71, 13.65]
Kasper (B) 2005 12 164 1 90 0.2% 6.59 [0.87, 49.83]
Kasper et al. 1995 43 110 11 108 1.5% 3.84 [2.09, 7.04]
Kasper et al. 2011 1 140 0 71 0.1% 1.53 [0.06, 37.13]
Kiev 1992 7 38 5 40 0.7% 1.47 [0.51, 4.25]
Learned et al. 2012 26 166 12 156 1.4% 2.04 [1.06, 3.89]
Lepola et al. (A) 2003 27 155 7 77 1.1% 1.92 [0.87, 4.20]
Lepola et al. (B) 2003 23 160 7 77 1.0% 1.58 [0.71, 3.52]
LVM-MD-06 6 79 4 93 0.5% 1.77 [0.52, 6.04]
Lydiard et al. 1989 6 18 4 18 0.6% 1.50 [0.51, 4.43]
Lydiard et al. 1997 14 132 12 129 1.2% 1.14 [0.55, 2.37]
Mao et al (2015) 10 19 0 18 0.1% 19.95 [1.25, 317.32]
McGrath et al. 2000 16 49 3 52 0.6% 5.66 [1.76, 18.23]
MY-1043/BRL-029060/115 (A) 76 284 7 59 1.2% 2.26 [1.10, 4.64]
MY-1043/BRL-029060/115 (B) 70 289 7 59 1.2% 2.04 [0.99, 4.21]
MY-1045/BRL-029060/1 (PAR128) (A) 107 357 11 70 1.7% 1.91 [1.08, 3.36]
MY-1045/BRL-029060/1 (PAR128) (B) 81 351 11 70 1.7% 1.47 [0.83, 2.61]
NCT00668525 (A) 41 322 8 109 1.2% 1.73 [0.84, 3.58]
NCT00668525 (B) 37 324 8 109 1.2% 1.56 [0.75, 3.24]
NCT01020799 7 50 4 99 0.5% 3.46 [1.06, 11.28]
NCT01473381 55 282 23 281 2.1% 2.38 [1.51, 3.77]
Nemeroff et al. 2007 22 104 8 102 1.1% 2.70 [1.26, 5.78]
Nierenberg et al (2007) 33 274 12 137 1.5% 1.38 [0.73, 2.58]
Norton et al. 1984 22 35 5 25 1.0% 3.14 [1.38, 7.17]
Olie et al.1997 26 129 12 129 1.4% 2.17 [1.14, 4.10]
PAR 29060.07.001 12 13 9 12 2.7% 1.23 [0.86, 1.77]
Perahia et al (2006) 6 97 1 99 0.2% 6.12 [0.75, 49.93]
Peselow et al. 1989a 8 40 4 42 0.6% 2.10 [0.69, 6.43]
Rapaport (A) 2008 18 164 6 89 0.9% 1.63 [0.67, 3.95]
Rapaport (B) 2008 18 173 7 89 1.0% 1.32 [0.57, 3.05]
Ratti et al. 2011 31 120 14 120 1.6% 2.21 [1.24, 3.95]
Reimherr et al. 1990 53 149 13 150 1.7% 4.10 [2.34, 7.20]
Rickels et al. 1986 4 18 3 24 0.4% 1.78 [0.45, 6.97]
Rickels et al. 1992 12 56 3 55 0.5% 3.93 [1.17, 13.16]
Roose 2004 6 87 6 90 0.6% 1.03 [0.35, 3.08]
Rudolph et al. 1999 20 103 14 98 1.5% 1.36 [0.73, 2.54]
Schatzberg 2006 23 100 14 96 1.6% 1.58 [0.86, 2.88]
Schneider 2003 59 171 20 376 2.1% 6.49 [4.04, 10.42]
SCT-MD 02 (A) 2002 20 125 8 64 1.1% 1.28 [0.60, 2.74]
SCT-MD 02 (B) 2002 18 123 8 63 1.1% 1.15 [0.53, 2.50]
SCT-MD-13 20 135 8 132 1.1% 2.44 [1.12, 5.35]
SCT-MD-26 14 154 9 155 1.0% 1.57 [0.70, 3.51]
SCT-MD-27 (A) 25 136 6 68 1.0% 2.08 [0.90, 4.84]
SCT-MD-27 (B) 24 138 6 67 1.0% 1.94 [0.83, 4.52]
SCT-MD-35 10 138 8 135 0.9% 1.22 [0.50, 3.00]
Sheehan et al. 2009 30 99 15 95 1.7% 1.92 [1.10, 3.33]
Shrivastava et al. 1992 10 40 3 40 0.5% 3.33 [0.99, 11.22]
Smith et al.1992 10 39 3 38 0.5% 3.25 [0.97, 10.90]
Sramek et al. 1995 17 72 8 72 1.1% 2.13 [0.98, 4.61]
Wade et al. 2002 17 191 7 189 0.9% 2.40 [1.02, 5.66]
Walczak et al. 1996 126 400 30 200 2.7% 2.10 [1.46, 3.01]
Wang et al 2014 47 156 30 155 2.4% 1.56 [1.04, 2.32]
WELL AK130927 30 138 21 141 1.9% 1.46 [0.88, 2.42]
Total (95% CI) 12257 8491 100.0% 2.09 [1.90, 2.30]
Total events 2524 779
Heterogeneity: Tau² = 0.05; Chi² = 129.71, df = 96 (P = 0.01); I² = 26%
Test for overall effect: Z = 15.45 (P < 0.00001)
0.01 0.1 1 10 100
Favours SSRI Favours placebo